It has been shown that the altered gene of the tumor suppressor PBRM1, which represents the second most common mutation in RCC (40%), is associated with longer progression-free survival and better treatment response to Sunitinib [11]. The gene discussed is PBRM1; the disease is renal cell carcinoma.